Johnson & Johnson Acquires Abiomed

Johnson & Johnson Completes Acquisition of V‑Wave Ltd.

October 9, 2024

Medical Devices

Johnson & Johnson has completed its acquisition of V‑Wave Ltd., adding V‑Wave’s Ventura Interatrial Shunt to the Johnson & Johnson MedTech portfolio. The transaction was accounted for as an asset acquisition and will result in an in‑process R&D charge of approximately $600 million as J&J expands its cardiovascular and heart‑failure capabilities.

Johnson & Johnson Acquires Shockwave Medical

April 5, 2024

Medical Devices

Johnson & Johnson will acquire Shockwave Medical for $335.00 per share in an all-cash transaction valued at approximately $13.1 billion including cash acquired. The deal adds Shockwave’s intravascular lithotripsy (IVL) technology to Johnson & Johnson MedTech, expanding J&J’s cardiovascular intervention portfolio and accelerating growth in high‑growth CAD and PAD markets.

Johnson & Johnson (Ethicon) Acquires Auris Health

April 1, 2019

Medical Devices

Johnson & Johnson, through its surgical devices unit Ethicon, completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash with up to $2.35 billion in contingent payments. The deal brings Auris' Monarch robotic bronchoscopy platform and related digital surgery capabilities into J&J's medical devices portfolio to accelerate capability expansion in digital and robotic surgery, particularly for lung cancer diagnosis and intervention.

Abbott Acquires Cardiovascular Systems, Inc.

February 8, 2023

Medical Devices

Abbott has agreed to acquire Cardiovascular Systems, Inc. (CSI) for $20.00 per share, representing an expected equity value of approximately $890 million. The acquisition adds CSI's orbital atherectomy system and early-stage vascular intervention pipeline to Abbott's vascular device portfolio to expand its capabilities in treating peripheral and coronary artery disease.

Danaher Corporation Acquires Abcam plc

August 28, 2023

Biotechnology

Danaher Corporation agreed to acquire Abcam plc for $24.00 per share, representing an enterprise value of approximately $5.7 billion including assumed indebtedness. Abcam, headquartered in Cambridge, United Kingdom, will operate as a standalone company within Danaher's Life Sciences segment; the transaction is expected to close in mid-2024 and is subject to customary approvals.

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.